Paolo Falvo, Stefania Orecchioni, Stefania Roma, Alessandro Raveane and Francesco Bertolini* Pages 2114 - 2136 ( 23 )
The costs of developing, validating and buying new drugs are dramatically increasing. On the other hand, sobering economies have difficulties in sustaining their healthcare systems, particularly in countries with an elderly population requiring increasing welfare. This conundrum requires immediate action, and a possible option is to study the large, already present arsenal of drugs approved and to use them for innovative therapies. This possibility is particularly interesting in oncology, where the complexity of the cancer genome dictates in most patients a multistep therapeutic approach. In this review, we discuss a) Computational approaches; b) preclinical models; c) currently ongoing or already published clinical trials in the drug repurposing field in oncology; and d) drug repurposing to overcome resistance to previous therapies.
Oncology, drug, repurposing, in silico, computational approaches, preclinical models, therapies.
Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, 20141 Milan, Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, 20141 Milan, Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, 20141 Milan, Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, 20141 Milan, Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, 20141 Milan